Eczema Drug's skin secrets under the microscope

NCT ID NCT05378698

Terminated Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, which could help predict who will respond best. The study included 20 patients and 5 healthy volunteers, but it was terminated early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tralokinumab
What this could lead to: If successful, this could help doctors identify which patients with atopic dermatitis are most likely to benefit from tralokinumab.
What could go wrong: This small, early-phase study was terminated, so results may be limited. It focuses on understanding the drug's mechanism, not on proving it works for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.